Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 38 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

21%

8 trials in Phase 3/4

Results Transparency

37%

14 of 38 completed trials have results

Key Signals

14 with results

Enrollment Performance

Analytics

Phase 1

21(56.8%)

Phase 2

8(21.6%)

Phase 3

7(18.9%)

Phase 4

1(2.7%)

37Total

Phase 1(21)

Phase 2(8)

Phase 3(7)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (38)

Showing 20 of 38 trials

NCT02078219Phase 2Completed

Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia

Role: collaborator

NCT03272425Phase 1Completed

Lesinurad/Allopurinol 200/300 Fixed-Dose Combination (FDC) Tablets Bioequivalence.

Role: lead

NCT02448368Phase 1Completed

RDEA3170 Tablet and Capsule Bioavailability Study

Role: lead

NCT01808144Phase 3Completed

Lesinurad and Febuxostat Combination Extension Study in Gout

Role: lead

NCT02498652Phase 2Completed

Phase 2a RDEA3170 and Allopurinol Combination Study in Gout Subjects

Role: lead

NCT02279641Phase 1Completed

RDEA3170 and Allopurinol Combination Study in Gout Subjects

Role: lead

NCT02336594Phase 1Completed

RDEA3170 Bioavailability Study

Role: lead

NCT02246673Phase 2Completed

RDEA3170 and Febuxostat Combination Study in Gout Subjects

Role: lead

NCT02888054Phase 1Completed

Lesinurad/Allopurinol 200/300 FDC Tablets Bioequivalence

Role: lead

NCT02219516Phase 1Completed

Mild, Moderate and Severe Renal Impairment Study

Role: lead

NCT02393560Completed

DECT Study in Allopurinol-Treated Gout Patients

Role: lead

NCT01808131Phase 3Completed

Lesinurad and Allopurinol Combination Extension Study in Gout

Role: lead

NCT01001338Phase 2Completed

Allopurinol Combination Study

Role: lead

NCT02581553Phase 1Completed

Lesinurad/Allopurinol 200/300 FDC Tablets Bioavailability

Role: lead

NCT02608710Phase 1Completed

RDEA3170 PK/PD Study

Role: lead

NCT01510158Phase 3Completed

Combining Lesinurad With Allopurinol in Inadequate Responders

Role: lead

NCT01493531Phase 3Completed

Combining Lesinurad With Allopurinol in Inadequate Responders

Role: lead

NCT01510769Phase 3Completed

Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat

Role: lead

NCT01650246Phase 3Completed

Open-Label Lesinurad Monotherapy Extension Study in Gout

Role: lead

NCT01508702Phase 3Completed

Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors

Role: lead